Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174258 | 0.89 | MCHR1 (0.40) | MCHR1HTR2CMCHR2MAPK7 | |
| SCHEMBL5668892 | 0.85 | HPGD (0.40) | MCHR1HTR2CMEN1KMT2A | |
| SCHEMBL5668886 | 0.85 | KMT2A (0.41) | MCHR1HTR2CMCHR2MEN1KMT2A | |
| SCHEMBL5669978 | 0.79 | CHRM2 (0.43) | MCHR1 | |
| SCHEMBL4389385 | 0.79 | TAOK1 (0.43) | MCHR1 | |
| SCHEMBL4387610 | 0.78 | KDM4E (0.42) | MCHR1MEN1KMT2A | |
| SCHEMBL5668246 | 0.78 | L3MBTL1 (0.49) | MEN1KMT2A | |
| SCHEMBL2172250 | 0.77 | MEN1 (0.45) | MCHR1MEN1KMT2A | |
| SCHEMBL2173905 | 0.76 | SHMT2 (0.43) | MCHR1MEN1KMT2A | |
| SCHEMBL2171393 | 0.76 | ALDH1A1 (0.42) | MCHR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | claimed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | MCHR1 3465/4885KDM1A 496/4885HRH3 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.